48th week of 2010 patent applcation highlights part 53 |
Patent application number | Title | Published |
20100305001 | FUNCTIONAL ASSAY FOR INDENTIFICATION OF LOSS-OF-FUNCTION MUTATIONS IN GENES - Provided herein are compositions and methods for assaying the deleteriousness of putative loss-of-function mutations, especially in genes known to be or suspected of being tumor-suppressor genes. The invention includes syngeneic variance libraries and methods of construction and use of syngeneic variance libraries. | 2010-12-02 |
20100305002 | Reagents and Methods for Producing Bioactive Secreted Peptides - This invention discloses reagents and methods for identifying peptides that modulate biological activities in cells, tissues, organs and organisms. | 2010-12-02 |
20100305003 | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides. | 2010-12-02 |
20100305004 | POLYNUCLEOTIDE BACKBONES FOR COMPLEXING PROTEINS - We use the Tus-Ter interaction to enable the utilization of nucleic acid analytical methodologies for proteins. We also use the Tus-Ter interaction to make polymers and oligomers that have a nucleic acid backbone with protein functionalities. These methods are useful for molecular modeling, for efficiently running enzymatic pathway reactions, and for analyzing presence and/or amount of particular proteins. | 2010-12-02 |
20100305005 | High-throughput cell transfection device and methods of using thereof - Transfecting biology cells with nucleic acid molecules (DNA, siRNA) is an essential prerequisite in elucidating how genes function in complex cellular context and how their activities could be modulated for therapeutic intervention. Traditionally studies are carried out on a low throughput gene-by-gene scale, which has created a huge bottleneck in functional genomic study and drug discovery. Development of high-throughput cell transfection technology will permit functional analysis of massive number of genes and how their activities could be modulated by chemical or biological entities inside cells. This invention describes design, construction of device and apparatus for high throughput effective cell transfection. Procedures and protocols for using the device and apparatus are also described in the application. Novel methods of using the device in cell-based assays are also disclosed. | 2010-12-02 |
20100305006 | Parallel Preparation of High Fidelity Probes in an Array Format - The present invention provides massively parallel oligonucleotide synthesis and purification for applications that utilize large collections of defined high-fidelity oligonucleotides (e.g., from about 10 | 2010-12-02 |
20100305007 | COPOLYMER BASED ON A SULFONIC ACID-CONTAINING COMPOUND - A copolymer containing, as monomer components, a) at least one sulfonic acid-containing compound, b) at least one nitrogen-containing N-vinylamide, one acrylamide or methacrylamide and c) at least one bifunctional or higher-functional vinyl ether is proposed. These copolymers are suitable in particular as thixotropic agents, antisegregation agents and water retention agents and overall as an additive in cement-containing but also gypsum-based systems. Such copolymers having a molecular weight of >40 000 g/mol can be used in particular as admixtures in the exploration of mineral oil and natural gas deposits. | 2010-12-02 |
20100305008 | Organophilic Clay Additives And Oil Well Drilling Fluids With Less Temperature Dependent Rheological Properties - An additive composition including a synergistic combination of a hectorite organoclay composition and an attapulgite organoclay composition. The hectorite organoclay composition includes (i) a first organic cation provided by an alkoxylated quaternary ammonium salt; and ii) a second organic cation wherein such second organic cation is not provided by an alkoxylated quaternary ammonium salt. The attapulgite organoclay composition includes (iii) a third organic cation provided by an alkoxylated quaternary ammonium salt; and (iv) a fourth organic cation wherein such third organic cation is not provided by an alkoxylated quaternary ammonium salt. | 2010-12-02 |
20100305009 | ADDITIVES FOR WATER-BASED DRILLING FLUIDS - The use of oligoglycerol fatty acid esters, prepared from | 2010-12-02 |
20100305010 | HIGH DENSITY PHOSPHATE BRINES AND METHODS FOR MAKING AND USING SAME - New heavy phosphate brines are disclosed, where the water soluble phosphate brines include two or more metal phosphate. Methods for making and using the heavy phosphate brines in drilling, completion, and fracturing operations are also disclosed. | 2010-12-02 |
20100305011 | ANTI-OXIDATION AND/OR ANTI-CORROSION AGENT, LUBRICATING COMPOSITION CONTAINING SAID AGENT AND METHOD FOR PREPARING THE SAME - New anti-oxidation and/or anti-corrosion agents representing new products resulting from the reaction of a diphenyl amine compound (DPA) with a phenyl-α-naphthyl amine compound (PAN), possess improved properties, as compared to known additives. Lubricating compositions, in particular for turbines, containing the novel anti-oxidation and/or anti-corrosion agents, and a method for preparing the novel anti-oxidation and/or anti-corrosion agents, as well as the novel lubricating compositions are described. | 2010-12-02 |
20100305012 | Lubricant Composition - A lubricant composition which is suitable as a fluorine oil, fluorine grease, and which is excellent in stabilizability, as well as a lubricant composition which is suitable as a fluorine oil, fluorine grease, and which has an excellent rust prevention property while keeping a heat resistance. | 2010-12-02 |
20100305013 | Bleach Delivery System and Method - A method and system for providing a disinfecting washcloth impregnable with bleach and having a pH under 7.0. Liquid bleach having a pH over 7.0 is provided in a frangible pouch, and is located with at least one absorbent washcloth in an outer package. A buffer of sufficient quantity and concentration when combined with the bleach is also provided, either already impregnating the washcloth or in a separate frangible pouch. The frangible pouches may also be located in yet another mixing pouch for mixing the liquid bleach and buffer before the absorbent washcloth is impregnated. | 2010-12-02 |
20100305014 | BIODEGRADABLE SURFACTANT BLEND - A degreasing composition is disclosed comprising an alkyl polyglucoside; and a nonionic surfactant having a carbon chain of C | 2010-12-02 |
20100305015 | SKIN CLEANSING COMPOSITIONS - An exfoliant body scrub having, as exfoliant, solid salt suspended in saturated brine containing sufficient surfactant to form, with said brine, a structured, solid suspending system, and optionally an oil dispersed in said brine. | 2010-12-02 |
20100305016 | AQUEOUS LIQUID COMPOSITION FOR PRE-TREATING SOILED DISHWARE - A liquid detergent composition comprising: from about 0.05 wt. % to about 5 wt. % of super wetting agent; from about 0.05 wt. % to about 10 wt. % of a non-ionic surfactant selected from short chain surfactants and branched surfactants; from about 0.05 wt. % to about 2 wt. % of a chelant; and from about 50 wt. % to about 95 wt. % of water. | 2010-12-02 |
20100305017 | Chlorinated Alkaline Pipeline Cleaner With Methane Sulfonic Acid - A chlorinated alkaline cleaning agent and methods for removing food soils with no resultant increase in foam generation. Particularly advantageous is that the addition of methanesulfonic acid in removing food soils with no resultant increase in foam generation. | 2010-12-02 |
20100305018 | ESTERIFIED ALKYL ALKOXYLATES AS SOLID LOW-FOAM WETTERS - The present invention relates to low-foam surfactant mixtures comprising esters of the general formula (I) | 2010-12-02 |
20100305019 | Hand Fabric Laundering System - An improved laundering system contains a laundry detergent and a rinsing composition. The laundry detergent is suitable for overnight soaking containing therein a bactericide and retards bacterial growth upon soaking a bacteria-contaminated fabric in a wash liquor for 6 hours at 25° C. The bactericide is selected from a bleach, an enzyme, and/or a surfactant. | 2010-12-02 |
20100305020 | WATER-SOLUBLE POUCH - The present application relates to a water soluble pouch comprising at least one compartment, wherein said compartment comprises a first liquid composition comprising an opacifier and an antioxidant and has a fresh Hunter L value of greater than 7 and a b value of less than 4. | 2010-12-02 |
20100305021 | PERFUME DELIVERY SYSTEMS FOR CONSUMER GOODS - The present invention relates to perfume delivery systems, products comprising such systems and the use of same. Unfortunately current perfume delivery systems do not always provide the most preferred or ideal sensory experience. Thus there is a need for one or more perfume delivery systems that obviate the short comings of the current perfume delivery technologies. The systems of the present invention meet the aforementioned need as they employ symbiotic combinations. | 2010-12-02 |
20100305022 | LOW MOLECULAR WEIGHT HEPARIN COMPOSITION AND USES THEREOF - Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided. | 2010-12-02 |
20100305023 | Method of Delaying The Onset of Clinically Definite Multiple Sclerosis - A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms. | 2010-12-02 |
20100305024 | METHODS OF INHIBITING CALCINEURIN WITH APOE ANALOGS - The present invention provides a method of modulating calcineurin activity in a cell by contacting the cell with at least one ApoE analog. Methods of treating various disorders associated with calcineurin activity using one or more ApoE analogs are also disclosed. In particular, the present invention provides a method of reducing demyelination and promoting remyelination in a subject. Methods of treating spinal cord or nerve injury in a subject are also described. | 2010-12-02 |
20100305025 | RNASE A PEPTIDES, FRAGMENTS AND USES THEREOF - The present invention features isolated polypeptides that have bactericidal and angiogenic activities. The invention features isolated polypeptides comprising amino acid sequences of RNase A ribonucleases, fragments and variants thereof, pharmaceutical compositions, and methods for treatment of a subject. | 2010-12-02 |
20100305026 | CD44V6 peptides as inhibitors of bacterial infections - The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection. | 2010-12-02 |
20100305027 | CYCLIC PEPTIDES COMPRISING AT LEAST ONE AZA-B3-AMINOACYL RESIDUE AND THEIR USES - Cyclic peptides having a random alternation of L-α-aminoacyl residues and aza-β | 2010-12-02 |
20100305028 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION - The present invention relates to compounds comprising at least ten contigous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus. | 2010-12-02 |
20100305029 | Paralytic Peptide for Use in Neuromuscular Therapy - The invention relates to a method of killing or immobilizing an insect comprising administering to the insect a low molecular weight peptide isolated from the submaxiliary saliva glands of shrews of the species | 2010-12-02 |
20100305030 | NANOPARTICLES OF THERAPEUTIC AGENTS HAVING LOW WATER SOLUBILITY - The invention relates to a water-dispersible derivative of a therapeutic agent having a low water solubility that comprises at least one molecule of said agent covalently bonded to at least one molecule of a hydrocarbon derivative having a squalenic structure or the like. The invention further relates to corresponding nanoparticles. | 2010-12-02 |
20100305031 | PEPTIDE HAVING AN EXTENDING ACTION FOR HALF-LIFE OF OBJECT PEPTIDE IN PLASMA - A peptide of the following (I) or (II).
| 2010-12-02 |
20100305032 | Novel GLP-1 Derivatives - Novel polypeptide derivatives having protracted profile of action. | 2010-12-02 |
20100305033 | HYDROXYALKYL STARCH DERIVATIVES AND PROCESS FOR THEIR PREPARATION - The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidised reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group, namely an acetal group or a ketal group. | 2010-12-02 |
20100305034 | GROWTH FACTOR ISOFORM - An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ.ID NO.1, or variants thereof. | 2010-12-02 |
20100305035 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative - The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above. | 2010-12-02 |
20100305036 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS - The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy. | 2010-12-02 |
20100305037 | CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS - The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: | 2010-12-02 |
20100305038 | DIAGNOSTIC OF IMMUNE GRAFT TOLERANCE USING TMTC3 GENE EXPRESSION LEVELS - The present invention concerns a method for the in vitro diagnosis or prognosis of a graft tolerant or graft non-tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising TMTC3 gene, optionally measuring other parameters, and determining the presence of a graft tolerant or graft non-tolerant phenotype from said expression profile and optional other parameters, wherein said method does not comprise determining an expression profile comprising, in addition to TMTC3, the following 7 genes: BUB1B, CDC2, CHEK1, MS4A1, RAB30, RHOH, and SYNGR3. Said method may further comprise, if said subject is diagnosed as a graft non-tolerant subject, diagnosing from the expression profile if said subject is developing chronic rejection. The present invention also relates to a medicament comprising a TMTC3 protein, or a fragment, an analogue or an analogue fragment thereof, in particular for the treatment, prevention, delay or inhibition of graft rejection. | 2010-12-02 |
20100305039 | Production of collagen in the milk of transgenic mammals - The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided. | 2010-12-02 |
20100305040 | PRODUCTION OF SOLUBLE RECOMBINANT PROTEIN BY PI VALUE CONTROL OF N-TERMINAL - The present invention relates to a method for improving secretion efficiency of a recombinant foreign protein using a polypeptide fragment containing N-region of a signal sequence (directional signal) or variants thereof with the controlled pI value and/or a secretional enhancer composed of a hydrophilic polypeptide with the controlled pI value. The method of the present invention can be not only useful for the production of a recombinant foreign protein by preventing precipitation of an insoluble precipitate and by increasing extracellular or extra-periplasmic secretion efficiency of a recombinant protein but also useful for the transduction of an effective therapeutic protein by increasing membrane permeability using a strong secretional enhancer. | 2010-12-02 |
20100305041 | CELL PERMEABLE P18 RECOMBINANT PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME, AND ANTICANCER COMPOSITION COMPRISING THE SAME - The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18 deficiency or failure which contains the cell permeable p18 recombinant protein as an effective ingredient. The cell permeable p18 recombinant proteins of the present invention are capable of efficiently introducing a haploinsufficient tumor suppressor p18 into a cell, and thus, can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent. | 2010-12-02 |
20100305042 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER - Compositions, kits, and methods are provided directed to the treatment of prostate cancer using a maintenance dose of degarelix or pharmaceutically acceptable salt thereof, an excipient, and a solvent. | 2010-12-02 |
20100305043 | CCL18 AND CCL3 METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CANCER - The invention relates to methods of treating cancer by administering one or more chemokines that are downregulated in cancerous cells. More specifically, the invention provides methods for treating or preventing cancers such as malignant melanoma by administering a chemokine such as CCL18 and/or CCL3. The invention further provides methods for diagnosing cancer such as melanoma. | 2010-12-02 |
20100305044 | PEPTIDE ANTI-TUMOR AGENT - Disclosed herein are isolated, purified peptides, biologically active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials. | 2010-12-02 |
20100305045 | OMEGA-3 OIL CONTAINING OPHTHALMIC EMULSIONS - Disclosed herein are non-irritating ophthalmic emulsion compositions useful for treating ocular disorders including dry eye. More specifically, the ophthalmic compositions disclosed herein combine a high HLB surfactant and a low HLB surfactant together with an omega-3 fatty acid-containing oil having non-polar aliphatic side chains to form a therapeutic non-irritating eye drop. | 2010-12-02 |
20100305046 | STABLE CYCLOSPORINE CONTAINING OPHTHALMIC EMULSION FOR TREATING DRY EYES - Disclosed herein are stable oil-in-water emulsion ophthalmic topical liquid compositions having an average particle size less than 1 μm including at least one plant-derived oil other than castor oil wherein the oil comprises only aliphatic side chains free of polar pendent groups. The oil-in-water emulsion ophthalmic topical liquid compositions also include a hydrophilic surfactant having an HLB value between approximately 10 and 14, a vegetable oil-derived hydrophobic non-co-block surfactant having unsaturated side chains that contain less than four oxygen atoms having an HLB value between approximately 4 and 6 and is a liquid at room temperature. The oil-in-water emulsion ophthalmic topical liquid compositions disclosed herein can further include an amount of cyclosporine A effective to relieve dry eye symptoms. | 2010-12-02 |
20100305047 | CYCLOSPORIN DERIVATIVES FOR ENHANCING THE GROWTH OF HAIR - The present invention provides a method for the treatment of alopecia and/or enhancing hair growth in a patient, wherein said method comprises administering, preferably topically, to the skin, e.g. the scalp or the eyelid, a therapeutically effective amount of a cyclosporin A derivative selected from the group consisting of compounds represented by the formula: | 2010-12-02 |
20100305048 | NOVEL USE OF CYTOKINE INHIBITORS - The use of substance that inhibits a pro-inflammatory cytokine, such as TNF or IL-1, for the production of a pharmaceutical composition for improving wound healing is disclosed. Also, a method for improving wound healing wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment is disclosed. | 2010-12-02 |
20100305049 | Novel Wheat Allergens - The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as bakers asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals. | 2010-12-02 |
20100305050 | PROTEIN PRODUCT WITH MODIFIED ANTIGENICITY - A bovine casein protein hydrolysate prepared using an enzyme having broad spectrum endopeptidase activity has low residual antigenicity properties in mammals compared to intact casein protein, The composition is useful as an ingredient in foods, beverages, pharmaceutical and cosmetic products. A hydrolysate prepared using Alcalase™ with a degree of hydrolysis of 19.88% has very desirably low antigenicity characteristics. | 2010-12-02 |
20100305051 | NATRIURETIC ACTIVITIES - This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided. | 2010-12-02 |
20100305052 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF - The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders. | 2010-12-02 |
20100305053 | USE OF HESPERIDIN OR OF A DERIVATIVE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF SLACKENED SKIN - The present invention relates to the oral use of an effective amount of hesperidin or of a derivative thereof as a skin finning agent. | 2010-12-02 |
20100305054 | CONCENTRATED AQUEOUS AZALIDE FORMULATIONS - The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the method comprising dissolving an azalide antibiotic in an aqueous solution comprising a strong acid. The invention also relates to methods for making concentrated aqueous azalide antibiotic formulations for use in pulmonary infection, a nasopharyngeal infection, an otic infection, an ocular infection, a dermal or a vaginal infection. The invention also relates to concentrated aqueous azalide antibiotic formulations made by dissolving an azalide antibiotic in an aqueous solution comprising a strong acid. | 2010-12-02 |
20100305055 | COMBINATIONS OF POLYENE FUNGICIDE WITH CATIONIC SURFACTANTS - A solid composition comprising a cationic surfactant, such as the ethyl ester of the lauramide of the arginine mono-hydrochloride (LAE) and a polyene fungicide such as natamycin is provided. The solid composition is the basis for providing solutions of natamycin of increased concentration. The solid composition may be used for providing a dispersion of natamycin in a suitable liquid, such as tap water or an organic solvent. The dispersion may be further diluted with water. This leads to a solution of natamycin in water. The combination of the cationic surfactant and the polyene fungicide displays a biological effect which is stronger than the effect of each of the two components alone. | 2010-12-02 |
20100305056 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE - Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis. Compounds of formula I of the invention are capable of treating and/or preventing the above-identified diseases: | 2010-12-02 |
20100305057 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER - A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination. | 2010-12-02 |
20100305058 | INDIVIDUALIZED CANCER TREATMENTS - The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments. | 2010-12-02 |
20100305059 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA - Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: | 2010-12-02 |
20100305060 | Nucleoside Prodrugs and Uses Thereof - This application provides compositions or compounds as disclosed herein that are suitable for treating hepatic viral diseases, such as hepatitis C(HCV). | 2010-12-02 |
20100305061 | MIXED BUTYRIC-FORMIC ESTERS OF ACID POLYSACCHARIDES, AND THEIR PREPARATION AND USE AS SKIN COSMETICS - Disclosed are acid polysaccharides characterised by the concomitant presence of alcohol groups esterified with butyric and formic acids. | 2010-12-02 |
20100305062 | USE OF ALGINATE OLIGOMERS IN COMBATING BIOFILMS - The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g., for disinfection and cleaning purposes. | 2010-12-02 |
20100305063 | Water-Soluble Iron Carbohydrate Derivative Complexes, The Preparation Thereof, And Medicaments Comprising Them - Water-soluble iron-carbohydrate derivative complex obtainable from an aqueous iron(III) salt solution and an aqueous solution of the product of the oxidation and subsequent derivatisation of one or more maltodextrins with an aqueous hypochlorite solution at an alkaline pH value, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of each individual maltodextrin in the mixture is from 2 to 40, and the subsequent derivatisation is carried out with a suitable reagent, process for the preparation thereof, and medicament for the treatment and prophylaxis of iron deficiency states. | 2010-12-02 |
20100305064 | TOPICAL SKIN CARE COMPOSITIONS - The present invention relates to an oil-in-water emulsion. The emulsion comprises a starch and a quaternary ammonium salt. The concentration of the quaternary ammonium salt is greater than about 0.5 percent by weight of the composition, the concentration of starch is greater than about 3 percent by weight of the composition, and the combined concentration of the quaternary ammonium salt plus the starch is greater than about 4 percent by weight of the composition. Methods of treating the skin are provided. | 2010-12-02 |
20100305065 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula wherein R | 2010-12-02 |
20100305066 | Fused Thiophene Derivatives as Kinase Inhibitors - A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 2010-12-02 |
20100305067 | ANTIBACTERIAL CONDENSED THIAZOLES - Compound of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C | 2010-12-02 |
20100305068 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING - Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for producing a protein and identifying compounds that rescue protein trafficking defects. | 2010-12-02 |
20100305069 | OXAZOLIDINONE CONTAINING DIMER COMPOUNDS, COMPOSITIONS AND METHODS TO MAKE AND USE - Dosage forms or pharmaceutical compositions comprise a compound having the structure of Formula IV: | 2010-12-02 |
20100305070 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer. | 2010-12-02 |
20100305071 | METHODS FOR IMPROVING HEALING OF AN ORAL LESION USING A GLYCEROPHOSPHATE SALT - Glycerophosphate salts have been found to hasten the healing and rapid scaling of lesions of the mouth. Methods are provided for improving healing of an oral lesion or preventing diseases or conditions related to an oral lesion using a glycerophosphate salt. In particular, methods are provided for preventing diseases or conditions related to an oral lesion using calcium glycerophosphate (CGP). | 2010-12-02 |
20100305072 | Substituted Tetracycline Compounds - The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms. | 2010-12-02 |
20100305073 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS - The present invention relates to compounds that have CYP | 2010-12-02 |
20100305074 | NIACIN-BASED PHARMACEUTICAL COMPOSITIONS - The disclosure relates generally to niacin-based pharmaceutical compositions that include at least one pharmaceutical agent capable of treating a niacin-induced side-effect. Accordingly, one aspect of this disclosure is a pharmaceutical composition for delivering niacin to a patient in need thereof, wherein the composition comprises a therapeutic dose of niacin and a therapeutically effective dose of at least one pharmaceutical agent capable of reducing an adverse side-effect of niacin in the patient, and wherein the pharmaceutical agent is delivered to the patient jointly with the niacin, preferably as a single dosage pill or tablet. | 2010-12-02 |
20100305075 | COMPOSITION AND METHOD OF TREATING HEARING LOSS - A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is greater than the effect of the individual components alone. The composition includes a biologically effective amount of vitamin E for inhibiting propagation of lipid peroxidation that contributes to hearing loss. The composition also includes a biologically effective amount of a salicylate for reducing hydroxyl radicals that contribute to hearing loss. A method of treating hearing loss includes the step of internally administering the composition, as described above, to a mammal within three days of trauma to a middle or inner ear of the mammal. In other words, the composition is effective even when administered as late as three days after trauma to a middle or inner ear of a mammal. | 2010-12-02 |
20100305076 | METHODS OF TREATMENT FOR ULCERATIVE COLITIS - Disclosed herein are new treatments for moderate ulcerative colitis in various subject subgroups. The various subject subgroups include Caucasians, non-smokers, subjects under the age of about 65 years, and subjects previously or currently being treated with steroids. | 2010-12-02 |
20100305077 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE - In one aspect, the present invention relates to amino-salicylic-aminophenylpropionic compounds for the use in the treatment of the inflammatory component of the celiac disease. These compounds act by blocking the cytokines released in the celiac disease and are specifically useful in the treatment of cases refractory to the diet, in dietary errors and in the reduction of the celiac disease remission time. | 2010-12-02 |
20100305078 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES - The presently disclosed subject matter is directed to metallo-oxidoreductase inhibitors having metal binding moities linked to a targeting moiety through a linking group or a direct bond, methods for screening for metallo-oxidoreductase inhibitors, and methods of treating an oxidoreductase related disorder by administering a metallo-oxidoreductase inhibitor to a subject in need of treatment thereof. | 2010-12-02 |
20100305079 | Method of Treating Human Preeclampsia Employing Resibufagenin - A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that preeclampsia does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has preeclampsia. In another embodiment, bufodienolide derivatives other than resibufagenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufagenin analogues may be employed in the treatment of preeclampsia. | 2010-12-02 |
20100305080 | Novel Crystalline Salts of Montelukast - The present application relates to crystalline 1,2-ethanedisulfonic acid salt and N,N′-dibenzylethylenediamine salt of montelukast. The salts are useful as therapeutic agents for the treatment of leukotriene mediated diseases and disorders. This application also relates to processes and intermediates for preparing the said salts and pharmaceutical compositions comprising the salts and optionally other therapeutic agents. | 2010-12-02 |
20100305081 | ORGANO-GEL FORMULATIONS FOR THERAPEUTIC APPLICATIONS - A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are compositions that further contain a cosmetic and/or pharmaceutical agent, along with the preparation and use thereof | 2010-12-02 |
20100305082 | Use of FKBPL gene to identify a cause of infertility - Fertility problems affect (1 in 10) couples in Western society, making it one of the most common serious health issues. Despite this, little is known about the causes of infertility, and thus patient counseling and treatment are suboptimal. With infertility being such a common problem, identification of any cause would impact on a large number of patients, allowing better counseling, clearer diagnoses and the possibility of making more informed choices (e.g. adoption vs. IVF treatment). The present invention provides methods to identify a cause of infertility in a subject based on the genotype of the subject, in particular, by evaluating the status of the gene encoding FK506 binding protein-like (FKBPL). In particular, the present invention relates to use of the status of the gene encoding FK506 binding protein-like for identification of a cause of an infertile phenotype in a subject. Also provided, are methods method for identifying an infertile phenotype in a subject, and identifying a cause of an infertile phenotype in a subject. This diagnostic tool finds wide clinical utility in the identification of a cause of infertility, resultantly impacting on a large number of patients. Further aspects of the present invention relate to the targeting of FKBPL in order to temporarily and reversibly induce infertility in a subject. Such aspects of the present invention find utility in the development of a male contraceptive pill. Moreover, due to the high degree of homology between the human and mouse FKBPL gene, FKBPL can be targeted in order to induce infertility in mice (or other species) as a form of pest control or animal husbandry. | 2010-12-02 |
20100305083 | SUBSTITUTED PORPHYRINS - To improve bioavailability of the catalytic metalloporphyrin-based SOD mimics Mn(III) 5,10,15,20-tetrakis[N-ethylpyridinium-2-yl]porphyrin (MnTE-2-PyP | 2010-12-02 |
20100305084 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE - Formula I (Ia and Ib) compounds wherein (i) X | 2010-12-02 |
20100305085 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES - The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds. | 2010-12-02 |
20100305086 | Pharmaceutical Compositions for the Treatment of Pain - This invention discloses a method of treatment of osteoarthritis pain by administration of a composition containing a nicotinic acetylcholine receptor ligand and a nicotinic acetylcholine receptor subtype α4β2 allosteric modulator. The present application also relates to compositions comprising such compounds for use in treating pain and related disorders mediated by controlling neurotransmitter release in a subject. | 2010-12-02 |
20100305087 | ACTIVE PHARMACEUTICAL INGREDIENT ON A SOLID SUPPORT, AMORPHOUS AND WITH AN IMPROVED SOLUBILITY - A combination preparation comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable solid support, wherein said solid support is in a water-insoluble particulate form and comprises a material selected from silicic acid, aluminum hydroxide and titanium hydroxide is disclosed. The API is a compound having both, at least one hydrophobic structural moiety causing the API to have a low solubility in water or in an aqueous solution, and multiple hydrophilic groups arranged to form multiple intermolecular interactions to the solid support involving polar or ionic or hydrogen bonding. The hydrophilic groups of the API are independently equal or different and comprise at least one of the groups consisting of OH- and halogen-groups. The API is bound to the solid support by adsorption, and a major proportion of said API is in an amorphous state. Related pharmaceuticals and methods of preparation also are disclosed. | 2010-12-02 |
20100305088 | INHIBITORS OF THE CHEMOKINE RECEPTOR CxCR3 - This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR | 2010-12-02 |
20100305089 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives - The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 2010-12-02 |
20100305090 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS - The invention relates to meta-substituted phenyl sulfonyl amides of secondary amino acid amides according to the general formula (I), (II), or (III), the production thereof, and the use thereof as matriptase inhibitors, in particular the use thereof as drugs for inhibiting tumor growth and/or metastasization. | 2010-12-02 |
20100305091 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES - Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau. | 2010-12-02 |
20100305092 | TRIAZOLE OXADIAZOLES DERIVATIVES - The invention relates to compounds of formula I: | 2010-12-02 |
20100305093 | Inhibitors of mTOR and Methods of Making and Using - The invention is directed to Compounds of Formula I: | 2010-12-02 |
20100305094 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA - Compounds of formula 1: | 2010-12-02 |
20100305095 | Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs - The present invention relates to, inter alia, the use of a compound capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The invention also provides for the use of a compound capable of inhibiting HPPD in an animal in the manufacture of a medicament for use in the treatment of the withdrawal symptoms associated with an addictive drug which causes dopamine dependant associative learning disorders in said animal. In a particular embodiment said HPPD inhibitor is selected from the group consisting of the compound depicted as compound 1; 2; and 3.22. | 2010-12-02 |
20100305096 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE - Formula I (Ia and Ib) compounds wherein (i) X | 2010-12-02 |
20100305097 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES - Compounds of Formula (I) | 2010-12-02 |
20100305098 | METHODS OF USE - A method of treating a disorder such as rheumatoid arthritis or multiple sclerosis in a subject is carried out by administering to the subject a composition comprising a modulator compound of Th1 differentiation or Th17 expansion. | 2010-12-02 |
20100305099 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION - The present invention encompasses compounds of general formula (1) wherein A, B, R | 2010-12-02 |
20100305100 | METHODS FOR TREATING HEPATITIS C - The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity. | 2010-12-02 |